ORIC vs. PHAT, IPHA, ARQT, KPTI, BTAI, BHC, MRVI, RYTM, DCPH, and ARVN
Should you be buying ORIC Pharmaceuticals stock or one of its competitors? The main competitors of ORIC Pharmaceuticals include Phathom Pharmaceuticals (PHAT), Innate Pharma (IPHA), Arcutis Biotherapeutics (ARQT), Karyopharm Therapeutics (KPTI), BioXcel Therapeutics (BTAI), Bausch Health Companies (BHC), Maravai LifeSciences (MRVI), Rhythm Pharmaceuticals (RYTM), Deciphera Pharmaceuticals (DCPH), and Arvinas (ARVN). These companies are all part of the "medical" sector.
Phathom Pharmaceuticals (NASDAQ:PHAT) and ORIC Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, community ranking, earnings, profitability, valuation, dividends and institutional ownership.
Phathom Pharmaceuticals received 24 more outperform votes than ORIC Pharmaceuticals when rated by MarketBeat users. Likewise, 68.27% of users gave Phathom Pharmaceuticals an outperform vote while only 66.20% of users gave ORIC Pharmaceuticals an outperform vote.
Phathom Pharmaceuticals has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, ORIC Pharmaceuticals has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500.
99.0% of Phathom Pharmaceuticals shares are held by institutional investors. Comparatively, 95.1% of ORIC Pharmaceuticals shares are held by institutional investors. 24.1% of Phathom Pharmaceuticals shares are held by company insiders. Comparatively, 5.6% of ORIC Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
ORIC Pharmaceuticals' return on equity of 0.00% beat Phathom Pharmaceuticals' return on equity.
ORIC Pharmaceuticals has lower revenue, but higher earnings than Phathom Pharmaceuticals. ORIC Pharmaceuticals is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Phathom Pharmaceuticals currently has a consensus target price of $22.00, suggesting a potential upside of 133.55%. ORIC Pharmaceuticals has a consensus target price of $20.00, suggesting a potential upside of 122.47%. Given ORIC Pharmaceuticals' higher possible upside, research analysts plainly believe Phathom Pharmaceuticals is more favorable than ORIC Pharmaceuticals.
In the previous week, Phathom Pharmaceuticals had 1 more articles in the media than ORIC Pharmaceuticals. MarketBeat recorded 7 mentions for Phathom Pharmaceuticals and 6 mentions for ORIC Pharmaceuticals. ORIC Pharmaceuticals' average media sentiment score of 0.69 beat Phathom Pharmaceuticals' score of 0.67 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media.
Summary
Phathom Pharmaceuticals beats ORIC Pharmaceuticals on 10 of the 16 factors compared between the two stocks.
Get ORIC Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ORIC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ORIC Pharmaceuticals Competitors List
Related Companies and Tools
